Table 5:

Prospective trials directly comparing sequencing of ICB and RT

Trial	ClinicalTrials.gov ID	Setting	Phase/Type	Treatment	Endpoint	Toxicity	Status
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer 46	NCT02635360	Locally advanced cervical cancer	2	Pembrolizumab given after or during chemoradiation	Safety	88% of patients with grade 2 or higher toxicity; no difference between arms	Early report published
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer73	NCT03738228	Node positive locally advanced cervix	1	Loading atezolizumab followed by chemoRT (extended field) versus chemoRT (extended field) with concurrent atezolizumab	Anti-tumor immune response	Pending Report	Active
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq)	NCT03307759	Metastatic non-smell lung cancer	1	Pembrolizumab given before or after SBRT	Adverse Events	Pending report	Recruiting